Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Structure Therapeutics Inc. has received a consensus rating of "Moderate Buy" from analysts, with one sell rating, seven buy ratings, and one strong buy rating.
• The company's average twelve-month price target among brokerages is $68.67, despite recent adjustments from firms like Guggenheim and JMP Securities.
• Structure Therapeutics reported a quarterly loss with earnings per share of ($0.36), missing analysts' expectations, as the company develops oral therapeutics for chronic diseases.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $68.6667.

A number of brokerages have recently weighed in on GPCR. Guggenheim dropped their price target on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a research note on Monday, September 8th. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $30.07 on Friday. The company has a market capitalization of $1.73 billion, a PE ratio of -28.64 and a beta of -1.65. The company has a 50-day simple moving average of $21.74 and a two-hundred day simple moving average of $21.23. Structure Therapeutics has a one year low of $13.22 and a one year high of $42.57.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, equities analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently bought and sold shares of the company. State of Wyoming purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $28,000. National Bank of Canada FI boosted its position in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares during the last quarter. Assetmark Inc. boosted its position in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after buying an additional 820 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after buying an additional 3,213 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company's stock valued at $92,000 after buying an additional 994 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.